I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 3 studies | 19% ± 3% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| glutamatergic neuron | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of NOMO2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| stomach | 100% | 593.55 | 358 / 359 | 96% | 8.83 | 274 / 286 |
| lung | 100% | 763.99 | 576 / 578 | 96% | 8.22 | 1106 / 1155 |
| esophagus | 96% | 492.79 | 1390 / 1445 | 99% | 10.58 | 181 / 183 |
| intestine | 99% | 586.92 | 959 / 966 | 96% | 7.35 | 504 / 527 |
| skin | 100% | 981.93 | 1801 / 1809 | 93% | 9.54 | 440 / 472 |
| breast | 100% | 575.85 | 459 / 459 | 92% | 8.17 | 1029 / 1118 |
| pancreas | 100% | 1311.79 | 328 / 328 | 89% | 5.20 | 159 / 178 |
| ovary | 99% | 478.34 | 178 / 180 | 88% | 7.01 | 377 / 430 |
| brain | 92% | 560.64 | 2422 / 2642 | 95% | 6.75 | 668 / 705 |
| bladder | 100% | 586.00 | 21 / 21 | 82% | 5.24 | 413 / 504 |
| prostate | 96% | 373.20 | 234 / 245 | 85% | 6.57 | 428 / 502 |
| thymus | 100% | 515.89 | 650 / 653 | 80% | 4.65 | 485 / 605 |
| uterus | 99% | 566.47 | 168 / 170 | 80% | 4.80 | 365 / 459 |
| kidney | 93% | 372.07 | 83 / 89 | 81% | 5.34 | 726 / 901 |
| adrenal gland | 94% | 548.06 | 243 / 258 | 68% | 5.50 | 157 / 230 |
| liver | 50% | 229.73 | 112 / 226 | 62% | 2.88 | 253 / 406 |
| blood vessel | 100% | 991.83 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 871.62 | 803 / 803 | 0% | 0 | 0 / 0 |
| adipose | 100% | 592.63 | 1203 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 99% | 416.77 | 238 / 241 | 0% | 0 | 0 / 0 |
| heart | 90% | 993.61 | 771 / 861 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 89% | 4.63 | 71 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 82% | 6.02 | 37 / 45 |
| peripheral blood | 71% | 410.71 | 656 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 48% | 2.80 | 14 / 29 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0160063 | Biological process | multi-pass transmembrane protein insertion into ER membrane |
| GO_0160064 | Cellular component | multi-pass translocon complex |
| GO_0032991 | Cellular component | protein-containing complex |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0043022 | Molecular function | ribosome binding |
| GO_0030246 | Molecular function | carbohydrate binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | NOMO2 |
| Protein name | NODAL modulator 2 BOS complex subunit NOMO2 (Nodal modulator 2) (pM5 protein 2) |
| Synonyms | |
| Description | FUNCTION: Component of the multi-pass translocon (MPT) complex that mediates insertion of multi-pass membrane proteins into the lipid bilayer of membranes . The MPT complex takes over after the SEC61 complex: following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex, the MPT complex occludes the lateral gate of the SEC61 complex to promote insertion of subsequent transmembrane regions . . |
| Accessions | ENST00000543392.5 [Q5JPE7-3] H3BPS9 ENST00000564991.5 ENST00000330537.10 [Q5JPE7-2] A0A087WTD5 ENST00000621364.4 [Q5JPE7-1] ENST00000562312.1 H3BNC4 ENST00000567831.5 ENST00000569051.1 ENST00000381474.7 [Q5JPE7-1] ENST00000620440.4 H3BTW1 H3BMJ6 Q5JPE7 ENST00000622306.5 [Q5JPE7-2] |
